−0.91USD
−7.94 MUSD
2.53 MUSD
5.54 M
About bioAffinity Technologies, Inc.
Sector
Industry
CEO
Maria Zannes
Website
Headquarters
San Antonio
Employees (FY)
75
Founded
2014
ISIN
US09076W1099
FIGI
BBG00H69JDX1
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BIAF is 2.84 USD — it has increased by 1.79% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange bioAffinity Technologies, Inc. stocks are traded under the ticker BIAF.
bioAffinity Technologies, Inc. is going to release the next earnings report on May 13, 2024. Keep track of upcoming events with our Earnings Calendar.
BIAF stock is 4.03% volatile and has beta coefficient of 1.38. Check out the list of the most volatile stocks — is bioAffinity Technologies, Inc. there?
BIAF earnings for the last quarter are −0.26 USD per share, whereas the estimation was −0.18 USD resulting in a −44.44% surprise. The estimated earnings for the next quarter are −0.20 USD per share. See more details about bioAffinity Technologies, Inc. earnings.
bioAffinity Technologies, Inc. revenue for the last quarter amounts to 298.48 K USD despite the estimated figure of 100.00 K USD. In the next quarter revenue is expected to reach 1.80 M USD.
Yes, you can track bioAffinity Technologies, Inc. financials in yearly and quarterly reports right on TradingView.
BIAF stock has risen by 14.52% compared to the previous week, the month change is a 40.59% rise, over the last year bioAffinity Technologies, Inc. has showed a 56.47% increase.
BIAF net income for the last quarter is −2.37 M USD, while the quarter before that showed −2.29 M USD of net income which accounts for −3.59% change. Track more bioAffinity Technologies, Inc. financial stats to get the full picture.
No, BIAF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BIAF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade bioAffinity Technologies, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 75.00 employees. See our rating of the largest employees — is bioAffinity Technologies, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So bioAffinity Technologies, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating bioAffinity Technologies, Inc. stock shows the strong buy signal. See more of bioAffinity Technologies, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. bioAffinity Technologies, Inc. EBITDA is −7.72 M USD, and current EBITDA margin is −304.98%. See more stats in bioAffinity Technologies, Inc. financial statements.